PLD and IFO As First-line Treatment for Patients With Advanced or Metastatic STS

• Status: Active, not recruiting
• Trial end date: 2020-12-30
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) for the first-line treatment of patients with advanced or metastatic soft tissue sarcoma (STS).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University
• Treatments: Doxorubicin; Ifosfamide

Criteria

Inclusion Criteria:

• aged 18-70 years with histologically confirmed advanced or metastatic STS

• Eastern Cooperative Oncology Group performance status of 0 to 2

• life expectancy of ≥ 3 months

• have not received chemotherapy before

• at least one measurable lesion

• LVEF≥50%

• have adequate bone marrow, hepatic, and renal function

Exclusion Criteria:

• osteosarcoma, Ewing's sarcoma/PNET (primitive neurotodermal tumour),GIST(Gastrointestinal Stromal Tumors), rhabdomyosarcoma, dermatofibrosarcoma protuberans

• patients with symptomatic brain metastases

• active clinical severe infection